BRAF targeted therapy for patients with melanoma and active brain metastases a review of clinical effectiveness
Skin cancer is the most common cancer in Canada, with about 6,500 new cases of skin malignant melanoma reported in 2014, and 1250 Canadians expected to die from it in 2017. Approximately 40-60% of melanomas contain a mutation in the gene that encodes BRAF, which leads to constitutive activation of d...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, October 18, 2017
|
| Edition: | Version 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Skin cancer is the most common cancer in Canada, with about 6,500 new cases of skin malignant melanoma reported in 2014, and 1250 Canadians expected to die from it in 2017. Approximately 40-60% of melanomas contain a mutation in the gene that encodes BRAF, which leads to constitutive activation of downstream signaling in the MAP (mitogen-activated protein) kinase pathway. This Rapid Response report aims to review the clinical effectiveness and safety of dabrafenib plus trametinib and cobimetinib plus vemurafenib for patients with BRAF (human gene that encodes a protein called B-Raf) mutation positive metastatic melanoma with active brain metastasis |
|---|---|
| Physical Description: | 1 PDF file (16 pages) illustrations |